{"id":143178,"date":"2023-03-06T05:43:52","date_gmt":"2023-03-06T10:43:52","guid":{"rendered":"https:\/\/44.250.171.167\/?p=143178"},"modified":"2023-03-06T05:43:53","modified_gmt":"2023-03-06T10:43:53","slug":"orchid-pharma-ltd-q3-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q3-fy23-earnings-conference-call-insights\/","title":{"rendered":"Orchid Pharma Ltd Q3 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Orchid Pharma Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/ORCHPHARMA\/\">ORCHPHARMA<\/a>) Q3 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:04:43] Himanshu Upadhyay from o3 Capital asked what changed in the DLL and Orchid merger that the merger opinion has been reversed. Manish Dhanuka MD said that the basic philosophy and intent behind the merger has not gone away, but a QIP is needed to meet MPS requirements. Once this is done, the merger will still be proposed in order to take advantage of synergies and have good governance structure.<\/li>\n<\/ul>\n<ul>\n<li>[00:08:36] Himanshu Upadhyay from o3 Capital queried what challenges are present and what efforts are being taken to increase the capacity utilization of oral products. Manish Dhanuka MD replied that the intent is to increase both sterile and oral output, however there are two factors that play a role in this. One is the contracts with major innovator companies, which varies. The other factor is increasing the sales of all other products, and ORCHID is heading towards achieving the goal.<\/li>\n<\/ul>\n<ul>\n<li>[00:12:32] Sajal Kapoor queried if contract research and manufacturing services is generic or NCE grants. Manish Dhanuka MD answered that it is generic and not NCE.<\/li>\n<\/ul>\n<ul>\n<li>[00:16:03] Sajal Kapoor asked about any execution risk on that 7ACA backward integration. Manish Dhanuka MD answered that ORCHPHARMA don&#8217;t anticipate many issues, but the only potential area could be technology. The company is in advanced negotiations with a reputable company for a technology transfer agreement and hope to sign it soon, so don&#8217;t foresee any problems right now.<\/li>\n<\/ul>\n<ul>\n<li>[00:17:17] Viraj Parekh from Carnelian asked that for 9 month FY23, how much revenue was contributed from Europe region. Mridul Dhanuka ED replied that it\u2019s calculated on an annual basis and last year, the company was between 40-45% and similar trend is expected to continue going forward. Additionally, US business started this year, but expect this number to be significant next year.<\/li>\n<\/ul>\n<ul>\n<li>[00:18:05] Viraj Parekh from Carnelian enquired about the expected demand environment in Europe in FY24. Mridul Dhanuka ED answered that the company is expecting a better demand this year. With the war going on, healthcare demand in Europe is expected to be higher.<\/li>\n<\/ul>\n<ul>\n<li>[00:18:49] \u00a0Viraj Parekh from Carnelian asked about the depreciation on a decrease, and if the company has to incur further capex for the outdated machinery. Mridul Dhanuka ED answered that Orchid has invested in world-class equipment and to maintain these assets, it will need INR15-20 crores in marginally capex. The company don&#8217;t need any major investments to maintain its current run-rate.<\/li>\n<\/ul>\n<ul>\n<li>[00:26:27] Nikhil Upadhyay at Securities Investment enquired about any developments on the sale of Orchid towers. Mridul Dhanuka ED said that the company has signed an ATS with a party, but hopefully the transaction should be concluded before end of March 2023.<\/li>\n<\/ul>\n<ul>\n<li>[00:31:43] Rupesh Jain of Intelsense queried about oral capacity utilization and what percentage of total revenue is contract manufacturing. Mridul Dhanuka ED clarified that the company has a long-term manufacturing deal with the innovator, but don&#8217;t do contract manufacturing.<\/li>\n<\/ul>\n<ul>\n<li>[00:34:07] Rupesh Jain of Intelsense asked about competition scenario with Nectar Lifesciences and others with ORCHID having strong balance sheet and management. Mridul Dhanuka ED answered that the markets are growing and the company is seeing healthy competition. The demand is growing and scope is there for everybody.<\/li>\n<\/ul>\n<ul>\n<li>[00:35:02] Rupesh Jain of Intelsense asked about the revenue contribution from US for the nine months FY23. Manish Dhanuka MD replied that currently the revenue contribution is in low single digit, but the CAGR percentage on this business would be much higher than the rest of the business in future.<\/li>\n<\/ul>\n<ul>\n<li>Darshan Jhaveri from Crown Capital asked about the proportion of oral and injectable sales. Mridul Dhanuka ED said about one-third of the business is injectables and two-thirds oral.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY23 Earnings Concall Q&amp;A Highlights: [00:04:43] Himanshu Upadhyay from o3 Capital asked what changed in the DLL and Orchid merger that the merger opinion has been reversed. Manish Dhanuka MD said that the basic philosophy and intent behind the merger has not gone away, but a QIP [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Orchid Pharma Ltd Q3 FY23 Earnings Conference Call Insights #ORCHPHARMA #Q3 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,1115],"class_list":["post-143178","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":127794,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":143178,"position":0},"title":"Orchid Pharma Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 22, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=z2DK9xz1c8k Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY22 Earnings Concall Q&A Highlights: Viraj Kacharia\u00a0 from Securities Investment asked about the DLL performance for the nine months of FY23 and comparison to previous year. Sunil Gupta CFO said that nine month EBITDA is INR10 crore and sale was INR300\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":137018,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":143178,"position":1},"title":"Orchid Pharma Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 22, 2022","format":false,"excerpt":"Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q2 FY23 Earnings Concall Q&A Highlights: [00:05:20] Rupesh Jain from Intelsense Capital asked about capacity utilization in 1H23. Mridul Dhanuka Director replied that on the sterile plant the utilization roughly is 90%. And the oral plant it\u2019s about 70%. [00:08:27] Rupesh Jain from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142258,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":143178,"position":2},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 17, 2023","format":false,"excerpt":"Orchid Pharma Ltd (NSE: ORCHPHARMA) Q3 FY23 Earnings Concall dated Feb. 17, 2023 Corporate Participants: Manish Dhanuka\u00a0--\u00a0Managing Director Mridul Dhanuka\u00a0--\u00a0Executive Director Sunil Kumar Gupta\u00a0--\u00a0Chief Financial Officer Analysts: Himanshu Upadhyay\u00a0--\u00a0o3 Capital -- Analyst Viraj Parekh\u00a0--\u00a0Carnelian Asset Advisors -- Analyst Sajal Kapoor\u00a0--\u00a0Independent Investor -- Analyst Tushaar Talwar\u00a0--\u00a0regulation30.com -- Analyst Nikhil Upadhyay\u00a0--\u00a0Securities Investment\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145872,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":143178,"position":3},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 11, 2023","format":false,"excerpt":"Orchid Pharma Ltd (NSE:ORCHPHARMA) Q4 FY23 Earnings Concall dated May. 11, 2023. Corporate Participants: Manish Dhanuka\u00a0--\u00a0Managing Director Mridul Dhanuka\u00a0--\u00a0Director Analysts: Himanshu Upadhyay\u00a0--\u00a0O3 BMS -- Analyst Rupesh Thapliyal\u00a0--\u00a0-- Analyst Nitesh Dutt\u00a0--\u00a0Burman Capital -- Analyst Sajal Kapoor\u00a0--\u00a0Individual Investor Nikhil\u00a0--\u00a0SIMPL -- Analyst Aditya Sen\u00a0--\u00a0Robocapital -- Analyst Tarang Agrawal\u00a0--\u00a0Old Bridge Capital -- Analyst Agastya\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135986,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-ltd-orchpharma-q1-fy23-earnings-concall-transcript\/","url_meta":{"origin":143178,"position":4},"title":"Orchid Pharma Ltd (ORCHPHARMA) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"August 10, 2022","format":false,"excerpt":"Orchid Pharma Ltd\u00a0(NSE:ORCHPHARMA) Q1 FY23 Earnings Concall dated Aug. 10, 2022 Corporate Participants: Mridul Dhanuka -- Executive Director Sunil Kumar Gupta -- Chief Financial Officer Manish Dhanuka -- Managing Director Analysts: Nishant Sabnis -- Sabnis Financial -- Analyst Nikhil Upadhyay -- SIMPL -- Analyst Unidentified Participant -- -- Analyst Viraj\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":128126,"url":"https:\/\/alphastreet.com\/india\/sanofi-india-ltd-q4-cy21-earnings-conference-call-insights\/","url_meta":{"origin":143178,"position":5},"title":"Sanofi India Ltd Q4 CY21 Earnings Conference Call Insights","author":"Praveen","date":"March 7, 2022","format":false,"excerpt":"https:\/\/youtu.be\/D2vfw6hB5RI Key highlights from Sanofi India Ltd (SANOFI) Q4 CY21 Earnings Concall Q&A Highlights: Vipul Shah of RippleWave Equity asked if the [analium] price impact already in 4QCY21 for Lantus. Rajaram Narayanan MD replied that the analium list has not been formally released. It is generally expected sometime in 1H22.\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=143178"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143178\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=143178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=143178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=143178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}